The global cell lysis & disruption market size is expected to reach US$ 7.1 billion by 2030 from US$ 3.7 billion in 2020 and is expected to grow at an impressive double-digit rate of 6.7% from 2021 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global cell lysis & disruption Market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1292
Crucial factors accountable for market growth are:
- Growing demand from the biopharmaceutical industry
- Rapid growth of the biopharmaceutical industry
- Presence of numerous biotechnology companies
- Increased investments in the research and development by the private players
- Development of the personalized medications
- Growing demand for the bioprocess solutions due to the development of biologics
- Rising adoption of ultrasonic homogenization
- Growing uses of instrument such as sonicators and homogenizers in cell fractionation
Report Scope of the Cell Lysis and Disruption Market
| Report Highlights | Details |
| Market Size | US$ 7.1 Billion by 2030 |
| Growth Rate | CAGR of 6.7% From 2021 to 2030 |
| Base Year | 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Cell Type, Application, End User, Region |
| By Product |
|
| By Application |
|
| Companies Mentioned | Thermo Fisher Scientific, Inc., Becton Dickinson & Company, Danaher Corporation, Qiagen NV, Parr Instrument Company, Claremont BioSolutions, Covaris Inc., Merck KGaA, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd. |
Market Dynamics
Drivers - The cell lysis & disruption market is primarily driven by the growing demand for the cell disruption technology and rising adoption of mammalian cell in the cell lysis industry. Further the rapid growth of the cell therapies and gene therapies owing to the growing preferences of the people in treatment of various chronic diseases is significantly boosting the market growth.
Restraints - The major retraining factors include high costs of the equipment used in the cell lysis & disruption and lack of skilled professionals. These are the major restraints that may hamper the market growth in the upcoming years. Moreover, the cell-based researches involve high costs and are a key restraint.
Opportunity - The emerging markets such as China, South Korea, India, and Brazil offers lucrative growth opportunities to the market players owing to the rising prevalence of various chronic disease, huge government expenditure in building healthcare infrastructure for facilitating research activities, and increasing penetration of research laboratories funded by the private players.
Challenges - The high costs involved may restrict the new entrants in the market and make the survival of the small players difficult. For surviving in the market, the players need to reduce their operational costs in order to focus on the research activities, which is very difficult for the small players in the market.
Report Highlights
- Based on the product, the instrument segment is estimated to be the most opportunistic market owing to the rising uses of instruments like blender, homogenizers, and sonicators. These instruments are very effective in extracting large samples and large volumes of mammalian cells with less oxidation during extraction.
- By cell type, the mammalian cells were the dominating segment in 2020. Mammalian cells have wide and extensive uses in the production of the key biopharma products like viral vaccines, gene based therapies, and cell-based therapies. The growing incidences of chronic diseases and increased adoption of gene therapies for treatment is exponentially propelling the segment growth.
- By application, the protein isolation dominated the market in 2020. The increased demand for the efficient protein extracting technologies is propelling the segment growth because of the loss of protein cells through oxidation during the extraction of proteins from the mammalian cells.
- By end use, the pharma & biotechnology companies registered the highest market share in 2020 due to the increased usage of cell lysis technology for conducting researches on the molecular bilogy.
Why should you invest in this report?
If you are aiming to enter the global cell lysis & disruption market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cell lysis & disruption are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the cell lysis & disruption market include:
- Thermo Fisher Scientific, Inc.
- Danaher Corporation
- Qiagen NV
- Parr Instrument Company
- Covaris Inc.
- Merck KGaA
- Bio-Rad Laboratories
- F. Hoffmann-La Roche Ltd.
- Claremont BioSolutions
- Becton Dickinson & Company
Market Segmentation:
By Product
- Instruments
- Reagents
By Cell Type
- Bacteria Cells
- Mammalian Cells
- Plant Cells
- Yeast/Fungi/Algae
By Application
- Cell Organelle Isolation
- Protein Isolation
- Downstream Processing
- Nucleic Acid Isolation
By End Use
- Hospitals and Diagnostic Laboratories
- Cell Banks
- Academic and Research Institutions
- Pharma & Biotechnology Companies
Regional Analysis:
The geographical analysis of the global cell lysis & disruption market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American market is again segmented into the US, Canada, and Mexico. Coming to the European market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global cell lysis & disruption Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global cell lysis & disruption market in 2030?
- What is the expected CAGR for the cell lysis & disruption market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global cell lysis & disruption market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Cell Lysis & Disruption Market, By Product
7.1. Cell Lysis & Disruption Market, by Product Type, 2021-2030
7.1.1. Instruments
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Reagents
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Cell Lysis & Disruption Market, By Application
8.1. Cell Lysis & Disruption Market, by Application, 2021-2030
8.1.1. Cell Organelle Isolation
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Protein Isolation
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Downstream Processing
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Nucleic Acid Isolation
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cell Lysis & Disruption Market, By Cell Type
9.1. Cell Lysis & Disruption Market, by Cell Type, 2021-2030
9.1.1. Bacteria Cells
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Mammalian Cells
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Plant Cells
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Yeast/Fungi/Algae
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cell Lysis & Disruption Market, By End Use Type
10.1. Cell Lysis & Disruption Market, by End Use Type, 2021-2030
10.1.1. End Use
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Cell Banks
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Academic and Research Institutions
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Pharma & Biotechnology Companies
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cell Lysis & Disruption Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.1.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.1.5.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.6.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.1.6.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.2.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.2.5.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.2.6.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.2.7.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.8.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.8.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.2.8.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.3.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.3.5.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.3.6.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.3.7.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.8.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.3.8.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.4.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.4.5.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.4.6.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.4.7.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.8.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.4.8.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.5.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.5.5.4. Market Revenue and Forecast, by End Use Type (2017-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.6.3. Market Revenue and Forecast, by Cell Type (2017-2030)
11.5.6.4. Market Revenue and Forecast, by End Use Type (2017-2030)
Chapter 12. Company Profiles
12.1. Thermo Fisher Scientific, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Danaher Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Qiagen NV
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Parr Instrument Company
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Covaris Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merck KGaA
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Bio-Rad Laboratories
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. F. Hoffmann-La Roche Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Claremont BioSolutions
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Becton Dickinson & Company
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1292
About Us:
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and among different ventures present globally.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments